Skip to content

1. (op 1/1/2020 zijn er 2 825020 vrouwen tss 10 en 49 jaar (op 1/1/2020 zijn er 2 825020 vrouwen tss 10 en 49 jaar

2. Munro, M., et al., The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. J Gynecol Obstet 2018;143:393-408.

3. Friberg B et al. Acta Obstet Gynecol Scand 1966;18:639

4. Fraser I et al. Health-related quality of life and economic burden of abnormal uterine bleeding. Exp Rev Obstet Gynecol 2009 4 (2); 179-189.

5. Karlsson T et al., Heavy menstrual bleeding significantly affects quality of life. Acta Obstet Gynecol Scand 2014;93(1): 52-57.

6. O’Brien et al., An Open-Label, Single-Arm, Efficacy Study of Tranexamic Acid in Adolescents with Heavy Menstrual Bleeding. J Pediatr Adolesc Gynecol 2019.

7. Haamid F et al., Heavy Menstrual Bleeding in Adolescents. J Pediatr Adolesc Gynecol 2017:30:335-340.

8. Davies J et al. Heavy menstrual bleeding: An update on management. Thromb Res 2017; 155 suppl 1: 70-77

9. Hallberg L et al., Determination of Menstrual Blood Loss. Scand J Clin LabInvest 1964;16:244–8.

10. Hallberg L et al., Menstrual Blood Loss and Iron Deficiency. Acta Med Scand 1966;18:639.

11. Munro, M., et al., The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them?. Am J Obstet Gynecol 2012;207:259.

12. Elmaoğulları et al. Abnormal Uterine Bleeding in Adolescents Abstract. 191 J Clin Res Pediatr Endocrinol 2018;10(3):191-197

13. Edlund M, et al. On the value of menorrhagia as a predictor for coagulationdisorders. Am J Hematol 1996;53(4):234–8.

14. Dilley A, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001;97(4):630–6

15. Munro MG, et al. FIGO classification system (PALM-COEIN) for causes ofabnormal uterine bleeding in nongravid women of reproductive age. Int JGynaecol Obstet 2011;113(1):3–13

16. Borzutsky, C., et al.,  Diagnosis and Management of Heavy Menstrual Bleeding and Bleeding Disorders in Adolescents. JAMA Pediatr 2020; 174 (2) 186-194.

17. Winikoff, R., Women and inherited bleeding disorders – A review with a focus on key challenges for 2019. Transfusion and Apheresis Science 58 (2019) 613–622

18. Deligeoroglou, E., et al., Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders. Best Practice & Research Clinical Obstetrics and Gynaecology 48 (2018) 51-61

19. RayS, et al., Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD010338. DOI: 10.1002/14651858.CD010338.pub3.

20. Caki Kilic, S., et al. Screening Bleeding Disorders in Adolescents and Yound Women with Menorrhagia. Turk J Haematol 2013; 30(2), 168-176.

21. De Wee, E., et al. Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thromb Haemost. 2011 Nov;106(5):885-92.

22. Gezondheidsnet. De menstruatiecyclus: verschillende fasen. [internet]. Available from [accessed June 2020]

23. Matteson KA, et al. Abnormal uterine bleeding, health status, and usual source of medical care: analyses using the medical expenditures panel survey. J Womens Health (Larchmt) 2013;22:959-965.

24. Moake, J. How Blood Clots. [internet] available from [accessed July 2020]

25. WFH, Inherited Bleeding Disorders. [internet] available from [accessed July 2020]

26. WFH, What is von Willebrand disease (VWD)?. [internet] available from [accessed July 2020]

27. WFH, symptoms and diagnosis. [internet] available from [accessed July 2020]

28. Leebeek F et al., Von Willebrand’s Disease. N Engl J Med 2016;375:2067-2080.

29. Peyvandi, F., et al., The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016; 388: 187–97

30. WFH, How do you get hemophilia?. [internet] available from [accessed July 2020]

31. Menegatti, M., et al. Treatment of rare factor deficiencies other than hemophilia. Blood 2019 Jan 31;133(5):415-424.

32. Dorgalaleh, A., et al. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016 Nov;30(6):461-475.

33. Poon, MC., et al. New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfus Med Rec 2016;30(2):92-99

34. Grainger, J., et al. How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J Haematol 2018 Sep;182(5):621-632.

35. Loomans, J., et al. Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica. 2018 Mar; 103(3): 550–557.

36. De ziekte van von willebrand. [internet] available from [accessed June 2020]

37. Tengborn, L., et al. Tranexamic acid–an old drug still going strong and making a revival. Thromb Res. 2015 Feb;135(2):231-42.

38. Srivastava, A., et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug;26 Suppl 6:1-158.

39. James, A., et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009 Jul;201(1):12.e1-8.

40. Kulkarni, R., Improving care and treatment options for women and girls with bleeding disorders. Eur J Haematol 2015 Dec;95 Suppl 81:2-10.

41. Committee on Adolescent Health Care; Committee on Gynecologic Practice. Committee Opinion No.580: von Willebrand disease in women. Obstet Gynecol. 2013 Dec;122(6):1368-73.

42. Janssen, C.A., et al. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol. 1995;85:977–82.

43. Magnay, J., et al. Pictorial methods to assess heavy menstrual bleeding in research and clinical practice: a systematic literature review. BMC Womens Health. 2020 Feb 10;20(1):24.

Back To Top